Sector: Health Care
Director information for LIGAND PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Jason Haas | Chief Financial Officer of Odyssey Therapeutics | 58 | ["Former Chief Financial Officer of Syros Pharmaceuticals","Former Co-Head of Americas, Healthcare Investment Banking at Barclays"] | [] | 2026 |
| Jason M. Aryeh | Founder and Managing General Partner of JALAA Equities, LP | 57 | [] | [] | 2026 |
| John L. LaMattina, Ph.D. | Senior Partner and Board Member at PureTech Health | 76 | ["Former President for Pfizer Global R&D"] | [] | 2026 |
| John W. Kozarich, Ph.D. | Co-Founder and Chief Executive Officer of Paludatus Pharmaceuticals | 76 | ["Former Chairman and President of ActivX Biosciences","Former Vice President for Merck Research Laboratories"] | [] | 2026 |
| Martine Zimmermann, Pharm.D. | Executive VP of Regulatory Affairs and Quality Assurance at Inventiva Pharma | 57 | [] | [] | 2026 |
| Nancy R. Gray, Ph.D. | President and Chief Executive Officer of Gordon Research Conferences | 66 | [] | [] | 2026 |
| Stephen L. Sabba, M.D. | Leading BioPharma Analyst and Fund Manager for Knott Partners, L.P. | 66 | [] | [] | 2026 |
| Todd C. Davis | Chief Executive Officer of Ligand Pharmaceuticals Incorporated | 65 | ["Co-Founder and Former Managing Partner of HealthCare Royalty Partners (now HCRx)"] | [] | 2026 |
